Price Alert

Armata Pharmaceuticals In... (ARMP)

AMEX: ARMP · Real-Time Price · USD

2.56

0.03 (1.19%)

At close: Aug 15, 2025, 1:06 PM

1.19% (1D)

Bid	2.48
Market Cap	92.75M
Revenue (ttm)	1.24M
Net Income (ttm)	-426K
EPS (ttm)	-1.07
PE Ratio (ttm)	-2.39
Forward PE	-3.21
Analyst	Strong Buy

Ask	2.56
Volume	8,906
Avg. Volume (20D)	247,509
Open	2.45
Previous Close	2.53
Day's Range	2.45 - 2.60
52-Week Range	0.90 - 2.96
Beta	1.00

About ARMP

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ARMP

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ARMP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Armata Pharmaceuticals Inc. is scheduled to release its earnings on Nov 12, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+75.56%

Armata Pharmaceuticals shares are trading after th... Unlock content with Pro Subscription

News

Just now · zacks.com

Is Armata Pharmaceuticals (ARMP) Outperforming Other Medical Stocks This Year?

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Avadel (AVDL) have performed compared to their sector so far this year.

3 days ago · zacks.com

Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates

Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.65 per share a year ago.

2 months ago · zacks.com

ARMP Soars 72% in a Month Following Infectious Disease Study Success

Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.